ESC Congress 2025

Primary Care Perspectives on late breaking trials and guideline updates

View here some expert perspectives with relevance for primary care on new clinical trials and guideline updates presented at the annual ESC congress 2025 held in Madrid

AMALFI: Active Monitoring for Atrial Fibrillation - Dr Nicholas Jones, University of Oxford, United Kingdom
Updated Guidelines on Dyslipidaemias - ESC/EAS Lipid Guidance Update on Supplements and vitamins - Prof Jeanine Roeters van Lennep, Rotterdam, The Netherlands
BaxHTN trial -Prof Richard Hobbs, University of Oxford, United Kingdom
Updated Guidelines on Dyslipidaemias - new approach to assess cardiovascular risk and reach treatment goals for lipid levels - Prof Jeanine Roeters van Lennep, Rotterdam, The Netherlands

Oct. 1, 2025

No Evidence Supports Vitamins or Supplements for Lowering LDL Cholesterol and Reducing Cardiovascular Risk

Primary care Perspectives on new ESC/EAS Lipid Guidance Update on Supplements and vitamins

Prof. Jeanine Roeters van Lennep provides a brief update on the new 2025 update to guidelines on Supplements Vitamins, LDL Cholesterol and CVD

Sep. 11, 2025

New guidance recommends a new approach to assess cardiovascular risk and reach treatment goals for lipid levels

Primary Care Perpectives on Updated Guidelines on Dyslipidaemias

Primary Care Perspective on the new ESC/EAS Focused Update to Guidelines about how best to manage lipid levels in patients to reduce cardiovascular risk with recommendation on the use of new cardiovascular risk predication algorithms.

Sep. 5, 2025

Blood-pressure reductions with baxdrostat in patients with uncontrolled or resistant hypertension

Primary Care Perspectives on the BaxHTN trial

Baxdrostat 1 mg or 2 mg once daily led to statistically significant reductions in blood pressure compared with placebo at 12 weeks in patients with uncontrolled or treatment-resistant hypertension, according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025

Sep. 2, 2025

Remote atrial fibrillation screening in primary care using an ECG patch demonstrates modest benefits

Primary Care Perspective on AMALFI: Active Monitoring for Atrial Fibrillation

View and read primary care perspectives on the investigator-initiated, parallel-arm unblinded randomised controlled AMALFI trial, eligible individuals were identified from 27 primary care practices in the UK via automated electronic health record searches